[go: up one dir, main page]

MX381503B - Métodos para la liberación de cromolina. - Google Patents

Métodos para la liberación de cromolina.

Info

Publication number
MX381503B
MX381503B MX2015016102A MX2015016102A MX381503B MX 381503 B MX381503 B MX 381503B MX 2015016102 A MX2015016102 A MX 2015016102A MX 2015016102 A MX2015016102 A MX 2015016102A MX 381503 B MX381503 B MX 381503B
Authority
MX
Mexico
Prior art keywords
methods
chromoline
release
cromolyn
aliergic
Prior art date
Application number
MX2015016102A
Other languages
English (en)
Other versions
MX2015016102A (es
Inventor
Alex Franzusoff
David R Elmaleh
Original Assignee
Aztherapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aztherapies Inc filed Critical Aztherapies Inc
Publication of MX2015016102A publication Critical patent/MX2015016102A/es
Publication of MX381503B publication Critical patent/MX381503B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con métodos para liberar cromolina a un paciente en necesidad del mismo, métodos de tratamiento de las afecciones amiloideas asociadas y enfermedades inflamatorias o alérgicas pulmonares y empaques de burbuja y kits que comprenden cromolina.
MX2015016102A 2013-05-23 2014-05-22 Métodos para la liberación de cromolina. MX381503B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361826798P 2013-05-23 2013-05-23
PCT/US2014/039118 WO2015002703A1 (en) 2013-05-23 2014-05-22 Methods for delivering cromolyn

Publications (2)

Publication Number Publication Date
MX2015016102A MX2015016102A (es) 2016-08-08
MX381503B true MX381503B (es) 2025-03-12

Family

ID=52144109

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015016102A MX381503B (es) 2013-05-23 2014-05-22 Métodos para la liberación de cromolina.
MX2020013362A MX2020013362A (es) 2013-05-23 2015-11-23 Metodos para la liberacion de cromolina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020013362A MX2020013362A (es) 2013-05-23 2015-11-23 Metodos para la liberacion de cromolina.

Country Status (9)

Country Link
US (1) US9861608B2 (es)
EP (1) EP2999337A4 (es)
JP (3) JP2016534976A (es)
CN (2) CN105377037A (es)
AU (4) AU2014284656B2 (es)
CA (1) CA2913235C (es)
HK (1) HK1218050A1 (es)
MX (2) MX381503B (es)
WO (1) WO2015002703A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
AU2013334874B2 (en) 2012-10-25 2018-04-05 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN105473133A (zh) 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CA2928028A1 (en) 2013-10-22 2015-04-30 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
ES2792682T3 (es) 2014-02-10 2020-11-11 Respivant Sciences Gmbh Métodos para el tratamiento de enfermedades pulmonares con estabilizadores de mastocitos
EP3653207A1 (en) 2014-02-10 2020-05-20 Respivant Sciences GmbH Mast cell stabilizers treatment for systemic disorders
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
JP2018534336A (ja) * 2015-11-19 2018-11-22 エーゼットセラピーズ， インコーポレイテッド アルツハイマー病および関連障害を処置するための方法
MX390748B (es) * 2015-11-23 2025-03-21 Massachusetts Gen Hospital Composiciones y metodos para tratar accidente cerebrovascular isquemico.
US20190240194A1 (en) 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
CN110139646A (zh) 2016-08-31 2019-08-16 瑞思皮万特科学有限责任公司 用于治疗由特发性肺纤维化引起的慢性咳嗽的色甘酸组合物
AU2017339366A1 (en) * 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
WO2018071425A1 (en) * 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
AU2017423862A1 (en) * 2017-07-20 2020-02-06 Aztherapies, Inc. Powdered formulations of cromolyn sodium and ibuprofen
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
KR102681843B1 (ko) 2017-09-22 2024-07-05 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
WO2019112552A1 (en) * 2017-12-04 2019-06-13 Aztherapies, Inc Cromolyn compositions and methods thereof
AU2019299347A1 (en) * 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
US20220218652A1 (en) * 2018-09-05 2022-07-14 The General Hospital Corporation Methods of treating cytokine release syndrome
WO2020097686A1 (en) * 2018-11-14 2020-05-22 Holman Pharmaceuticals Pty Ltd Compositions and uses thereof
SG11202106117SA (en) * 2018-12-10 2021-07-29 Massachusetts Gen Hospital Cromolyn esters and uses thereof
US12458622B2 (en) 2020-04-06 2025-11-04 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69034007T2 (de) * 1989-04-28 2003-05-08 Riker Laboratories Inc., Northridge Inhalationsvorrichtung für Trockenpulver
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5989396A (en) 1997-04-02 1999-11-23 Eltech Systems Corporation Electrode and electrolytic cell containing same
NZ503464A (en) * 1997-09-29 2002-05-31 Inhale Therapeutic Syst Perforated microparticles containing a bioactive agent for pulmonary delivery
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
JP2001151673A (ja) * 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
US20040223918A1 (en) 2003-05-07 2004-11-11 Chrysalis Technologies Incorporated Aerosolization of cromolyn sodium using a capillary aerosol generator
US8263645B2 (en) * 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
US20090110679A1 (en) 2007-07-13 2009-04-30 Luk-Chiu Li Methods and compositions for pulmonary administration of a TNFa inhibitor
GB0714134D0 (en) 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
US8617517B2 (en) * 2009-01-29 2013-12-31 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
ES2457442T3 (es) * 2009-05-08 2014-04-25 Pari Pharma Gmbh Formulaciones farmacéuticas concentradas estabilizadoras de los mastocitos
WO2011136754A1 (en) 2010-04-26 2011-11-03 Mahmut Bilgic A medicament developed for the treatment of respiratory diseases
AU2013334874B2 (en) * 2012-10-25 2018-04-05 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
JP2019073921A (ja) * 2017-10-17 2019-05-16 アイシン精機株式会社 車両用ドアチェック装置

Also Published As

Publication number Publication date
CN110652495A (zh) 2020-01-07
AU2014284656A2 (en) 2016-01-21
CA2913235A1 (en) 2015-01-08
WO2015002703A1 (en) 2015-01-08
CA2913235C (en) 2021-07-13
HK1218050A1 (zh) 2017-02-03
US9861608B2 (en) 2018-01-09
JP2021181493A (ja) 2021-11-25
AU2014284656B2 (en) 2017-11-23
MX2020013362A (es) 2021-03-09
AU2022200260A1 (en) 2022-02-10
US20160106704A1 (en) 2016-04-21
AU2017254974A1 (en) 2017-11-23
JP2016534976A (ja) 2016-11-10
AU2014284656A1 (en) 2016-01-21
AU2019271898A1 (en) 2019-12-19
JP2019112468A (ja) 2019-07-11
MX2015016102A (es) 2016-08-08
CN105377037A (zh) 2016-03-02
AU2019271898B2 (en) 2022-02-03
AU2019271898C1 (en) 2022-06-09
EP2999337A4 (en) 2017-03-15
EP2999337A1 (en) 2016-03-30

Similar Documents

Publication Publication Date Title
MX381503B (es) Métodos para la liberación de cromolina.
CY1121736T1 (el) Άλατα aramchol
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
DK3204095T3 (da) Inhalationsindretning til anvendelse i aerosolbehandling af luftsvejssygdomme
BR112015023533A2 (pt) plataforma de descoberta celular para doenças neurodegenerativas
BR112015002524A2 (pt) derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
HUE040044T2 (hu) Fumarátok prodrugjai, és azok alkalmazása különbözõ betegségek kezelésében
IL246141A0 (en) Methods for adhering tissue surfaces and materials and biomedical uses thereof
IL237592B (en) Methods of expanding and assessing b cells and using expanded b cells to treat disease
DK3461491T3 (da) Forbedret adoptiv celleterapi
IL235512B (en) Phenylbenzamide derivatives for use in treating diseases mediated by aquaporin
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
DK3909966T3 (da) 19-nor c3,3-disubstitueret c21-n-pyrazolylsteroid til brug i behandling
EP3003139C0 (en) MODULAR PHYSIOLOGICAL MONITORING SYSTEMS, KITS AND METHODS
IL239735A0 (en) Treatment and diseases associated with toxic aldehyde
DK3027208T3 (da) Cancerdiagnose og -terapi, der involverer cancerstamceller
HUE051632T2 (hu) Betegségek kezelésére szolgáló készítmények és eljárások
EP2968801A4 (en) METHOD FOR THE TREATMENT OF RESPIRATORY DISEASES AND FORMULATIONS THEREFOR
PT2872497T (pt) Derivados de cromanilo para o tratamento de doenças mitocondriais
IL242137B (en) Methods and compositions for wound healing
LTPA2020511I1 (lt) Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui
LT3735962T (lt) Farmacinė kompozicija, apimanti fosfatus surišančias daleles
EP2970492A4 (en) ANTIBODY AGAINST HUMAN AND DOG IL-13RA2
EP2990230A4 (en) TIRE
IL234606B (en) Novel methods and composition for treatment of disease